Stryker Corporation

Equities

SYK

US8636671013

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 03:33:30 2024-03-28 pm EDT 5-day change 1st Jan Change
358.6 USD -0.04% Intraday chart for Stryker Corporation +1.32% +19.61%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Stryker Launches Gamma4 Hip Fracture Nailing System in Europe CI
Activist investor Politan plans second proxy battle at Masimo, WSJ reports RE
Stryker Completes Acquisition of French Joint Replacement Firm Serf MT
Stryker Corporation completed the acquisition of Serf from SAS Menix. CI
Stryker Insider Sold Shares Worth $2,756,730, According to a Recent SEC Filing MT
Transcript : Stryker Corporation Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 01:45 PM
The latest transactions by star fund managers Our Logo
Stryker Insider Sold Shares Worth $3,290,952, According to a Recent SEC Filing MT
Stryker Insider Sold Shares Worth $100,349,381, According to a Recent SEC Filing MT
Stryker Keeps Quarterly Dividend at $0.80 a Share, Payable April 30 to Shareholders as of March 29 MT
Fed officials fail to convince investors, who are focused on earnings Our Logo
Stryker Declares Quarterly Dividend, Payable on April 30, 2024 CI
ANALYST RECOMMENDATIONS : Caterpillar, Eli Lilly, Intel, Meta, T-Mobile... Our Logo
DA Davidson Raises Price Target on Stryker to $355 From $305, Cites Strong Sales Results, Keeps Buy/Add Rating MT
UBS Adjusts Stryker Price Target to $339 From $331, Maintains Neutral Rating MT
Deutsche Bank Raises Stryker Price Target to $345 From $300, Maintains Hold Rating MT
Citigroup Raises Price Target on Stryker to $362 From $340, Keeps Buy Rating MT
Evercore ISI Raises Price Target on Stryker to $340 From $320, Keeps Outperform Rating MT
Piper Sandler Adjusts Price Target on Stryker to $375 From $360, Keeps Overweight Rating MT
JPMorgan Raises Price Target on Stryker to $375 From $325, Keeps Overweight Rating MT
Canaccord Genuity Upgrades Stryker to Buy From Hold, Price Target is $360 MT
Roth MKM Raises Price Target on Stryker to $348 From $345, Keeps Buy Rating MT
TD Cowen Raises Price Target on Stryker to $365 From $322, Keeps Outperform Rating MT
Baird Raises Price Target on Stryker to $367 From $319, Keeps Outperform Rating MT
Jefferies Adjusts Price Target on Stryker to $390 From $345, Keeps Buy Rating MT
Chart Stryker Corporation
More charts
Stryker Corporation is one of the world's leaders in designing, manufacturing, and selling orthopedic equipments. Net sales break down by family of products as follows: - surgical equipments and neurotechnology products (57.5%): electric motorized surgical instruments, surgical navigation systems, endoscopy equipment, digital imaging systems, neurosurgery equipments, neurovascular devices, etc. The group also offers hospital beds, gurneys, stretchers, and emergency room equipment; - orthopedic implants (42.5%): joint prostheses, traumatology implants, micro-implants, orthopedic cement, orthobiology products, etc. The group also provides spinal implants. At the end of 2022, the group had 48 production sites worldwide. Net sales are distributed geographically as follows: the United States (73.9%), Europe/Middle East/Africa (12.7%), Asia/Pacific (10.2%) and other (3.2%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
358.7 USD
Average target price
356.8 USD
Spread / Average Target
-0.54%
Consensus
  1. Stock
  2. Equities
  3. Stock Stryker Corporation - Nyse
  4. News Stryker Corporation
  5. Stryker : Ups Q1 Adjusted Earnings, Revenue; Sets FY21 Outlook